César Remón

César Remón

Auto-generated profile, based on publicly available information

César Remón

Hospital Universitario Puerto Real, Cádiz, Spain

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2015 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
MLMoniek W.M. van de Luijtgaarden
Moniek W.M. van de Luijtgaarden
KJKitty J. Jager
Kitty J. Jager
MSMårten Segelmark
Mårten Segelmark
JPJulio Pascual
Julio Pascual
FCFrederic Collart
Frederic Collart
MNMarlies Noordzij
Marlies Noordzij
Although previous studies suggest similar patient survival for peritoneal dialysis (PD) and haemodialysis (HD), PD use has decreased worldwide. We aimed to study trends in the choice of first dialysis modality and relate these to variation in patient and technique survival and kidney transplant rates in Europe over the last 20 years. We used data from 196 076 patients within the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry who started renal replacement therapy (RRT) between 1993 and 2012. Trends in the incidence rate and prevalence on Day 91 after commencing RRT were quantified with Joinpoint regression. Crude and adjusted hazard ratios (HRs) for 5-year dialysis patient and technique survival were calculated using Cox regression. Analyses were repeated using propensity score matching to control for confounding by indication. PD prevalence dropped since 2007 and HD prevalence stabilized since 2009. Incidence rates of PD and HD decreased from 2000 and 2009, respectively, while the incidence of kidney transplantation increased from 1993 onwards. Similar 5-year patient survival for PD versus HD patients was found in 1993–97 [adjusted HR: 1.02, 95% confidence interval (95% CI): 0.98–1.06], while survival was higher for PD patients in 2003–07 (HR: 0.91, 95% CI: 0.88–0.95). Both PD (HR: 0.95, 95% CI: 0.91–1.00) and HD technique survival (HR: 0.93, 95% CI: 0.87–0.99) improved in 2003–07 compared with 1993–97. Although initiating RRT on PD was associated with favourable patient survival when compared with starting on HD treatment, PD was often not selected as initial dialysis modality. Over time, we observed a significant decline in PD use and a stabilization in HD use. These observations were explained by the lower incidence rate of PD and HD and the increase in pre-emptive transplantation.

1 April 2008 in Kidney International
Verified
Journal Article
Closed access
BMB. Marrón
B. Marrón
CRC. Remón
C. Remón
MPM. Pérez-Fontán
M. Pérez-Fontán
PQP. Quirós
P. Quirós
AOAlberto Ortiz
Alberto Ortiz

14 October 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMario Prieto-Velasco
Mario Prieto-Velasco
PQPedro Quiros
Pedro Quiros
CRCesar Remon
Cesar Remon
JFJuan Manuel Buades Fuster
Juan Manuel Buades Fuster
It is desirable for patients to play active roles in the choice of renal replacement therapy (RRT). Patient decision aid tools (PDAs) have been developed to allow the patients to choose the option best suited to their individual needs. An observational, prospective registry was conducted in 26 Spanish hospitals between September 2010 and May 2012. The results of the patients’ choice and the definitive RRT modality were registered through the progressive implementation of an Education Process (EP) with PDAs designed to help Chronic Kidney Disease (CKD) patients choose RRT. Patients included in this study: 1044. Of these, 569 patients used PDAs and had made a definitive choice by the end of registration. A total of 88.4% of patients chose dialysis [43% hemodialysis (HD) and 45% peritoneal dialysis (PD)] 3.2% preemptive living-donor transplant (TX), and 8.4% conservative treatment (CT). A total of 399 patients began RRT during this period. The distribution was 93.4% dialysis (53.6% HD; 40% PD), 1.3% preemptive TX and 5.3% CT. The patients who followed the EP changed their mind significantly less often [kappa value of 0.91 (95% CI, 0.86–0.95)] than those who did not follow it, despite starting unplanned treatment [kappa value of 0.85 (95% CI, 0.75–0.95]. A higher agreement between the final choice and a definitive treatment was achieved by the EP and planned patients [kappa value of 0.93 (95% CI, 0.89–0.98)]. Those who did not go through the EP had a much lower index of choosing PD and changed their decision more frequently when starting definitive treatment [kappa value of 0.73 (95% CI, 0.55–0.91)]. Free choice, assisted by PDAs, leads to a 50/50 distribution of PD and HD choice and an increase in TX choice. The use of PDAs, even with an unplanned start, achieved a high level of concordance between the chosen and definitive modality.

1 March 2015 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Closed access
PDF file
GPGloria del Peso
Gloria del Peso
JJJosé Antonio Jiménez-Heffernan
José Antonio Jiménez-Heffernan
RSRafael Selgas
Rafael Selgas
CRCésar Remón
César Remón
MOMarta Ossorio
Marta Ossorio
MBMaría Auxiliadora Bajo
María Auxiliadora Bajo
Introduction: Chronic exposure to conventional peritoneal dialysis (PD) solutions has been related to peritoneal function alterations in PD patients, and associated with mesothelial cell loss, submesothelial fibrosis, vasculopathy, and angiogenesis. In vitro and ex vivo analyses, as well as studies with animal models, have demonstrated that biocompatible PD solutions attenuate these morphological alterations. Our aim was to confirm the morphological benefits of biocompatible solutions in PD patients. Methods: We analyzed biopsies from 23 patients treated with biocompatible solutions (study group, SG), and compared them with a control group ( n = 23) treated with conventional solutions (CG), matched for time on PD. Results: A total of 56.5% of SG patients showed total or partial preservation of mesothelial cells monolayer, in contrast with 26.1% of patients in CG ( p = 0.036). Peritoneal fibrosis was not significantly less frequent in SG patients (47.8% SG vs 69.6% CG; p = 0.13). In patients without previous peritonitis, a significantly lower prevalence of fibrosis was present in SG patients (41.7% SG vs 77.8% CG; p = 0.04). Hyalinizing vasculopathy (HV) was significantly lower in SG (4.3% SG vs 30.4% CG; p = 0.02). Cytokeratin-positive fibroblast-like cells were detected in 10 patients (22%), but the prevalence was not significantly lower in SG. In the univariate regression analysis, the use of biocompatible solutions was associated with mesothelial monolayer integrity ( p = 0.04) and an absence of vasculopathy ( p = 0.04). Conclusion: The present study demonstrates in vivo in human biopsies that biocompatible solutions are better tolerated by the peritoneum in the medium and long term than conventional solutions.

1 September 2013 in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Verified
Journal Article
Open access
PDF file
SRSilvia Ros
Silvia Ros
CRCesar Remón
Cesar Remón
AQAbdul Rashid Qureshi
Abdul Rashid Qureshi
PQPedro Quiros
Pedro Quiros
BLBengt Lindholm
Bengt Lindholm
JCJuan Jesús Carrero
Juan Jesús Carrero
♦ Background and Objectives: Although cardiovascular disease (CVD) is an important cause of morbidity and mortality in patients with end-stage renal disease, non-CVD causes account for more than 50% of total deaths. We previously showed that, compared with men, women starting dialysis— both hemodialysis and peritoneal dialysis (PD)—have higher non-CVD mortality rates. Here, we evaluate sex-specific outcomes in a large cohort of incident PD patients.

31 July 2018 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
GOGurbey Ocak
Gurbey Ocak
MNMarlies Noordzij
Marlies Noordzij
MRMaarten B. Rookmaaker
Maarten B. Rookmaaker
ACAleix Cases
Aleix Cases
CCCécile Couchoud
Cécile Couchoud
KJKitty J. Jager
Kitty J. Jager